TY - JOUR T1 - Apoptosis-related Proteins Are Altered by Selective Tyrosine Kinase Inhibitors and Everolimus in HPV-dependent SCC JF - Anticancer Research JO - Anticancer Res SP - 6195 LP - 6203 DO - 10.21873/anticanres.14639 VL - 40 IS - 11 AU - RICHARD BIRK AU - ANGELA SCHELL AU - CHRISTOPH ADERHOLD AU - STEPHAN HOCH AU - LENA HUBER AU - CORNELIA EMIKA MUELLER AU - ANNE LAMMERT AU - CLAUDIA SCHERL AU - NICOLE ROTTER AU - J. ULRICH SOMMER AU - BENEDIKT KRAMER Y1 - 2020/11/01 UR - http://ar.iiarjournals.org/content/40/11/6195.abstract N2 - Background: Head and neck squamous cell cancer (HNSCC) affects the oral cavity and the pharynx. The aim of the study was to investigate the effects of selective tyrosine kinase inhibitors (TKIs) erlotinib, gefitinib, nilotinib and dasatinib and the mammalian target of rapamycin (mTOR) inhibitor everolimus on the expression of apoptosis-related proteins caspase-3, FAS cluster of differentiation (CD)-95 and FAS ligand in human papilloma virus (HPV)-dependent squamous cancer. Materials and Methods: Two HPV-negative cell lines (UMSCC-11A/-14C) and one HPV-positive cell line (CERV196) were incubated with TKIs or everolimus and protein concentrations of target proteins were analyzed with enzyme-linked immunosorbent assay (ELISA). Results: Caspase-3 was affected by the tested TKIs in HPV-positive SCC, whereas FAS CD95 and FAS ligand were influenced in HPV-negative SCC. Discussion: This is the first study to analyze the influence of TKIs and everolimus on key proteins of apoptosis. Our results provide novel information contributing to a better understanding of the cell biology of HPV-dependent HNSCC and might contribute to the discovery of novel pharmaceutical treatment strategies for HNSCC. ER -